QRONO, INC

Biotech · Private

QR401, an oral nanoparticle-based AMPK pathway agonist that targets antigen presenting cells in the intestine

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026

Sector: Biotech
Total capital: $5.8M

Federal grants: $915K; 3 awards · 2024–2025; Rank in peer group#5 of 502
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $4.9M; 8 awards · Defense, Health and Human S; Rank in Biotech#81 of 4373
Granted patents: 0; 6 pending

Capital timeline

Latest events

Aug 2025Federal grantHealth and Human S · Phase I · Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.$302K
Sep 2024Federal grantHealth and Human S · Phase I · Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.$306K
Jul 2024Federal grantHealth and Human S · Phase I · Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes$307K
Sep 2023Federal contractHealth and Human S · Screening For Tolerogenic Adjuvants To Enhance Antigen Specific Immunotherapy For Celiac Disease.$600K
Jan 2022Federal contractHealth and Human S · Apc Specific Mtop Inhibition Potentiates Immune Response To Iiv In Elderly Recipients.$598K
Sep 2016Federal contractHealth and Human S · Igf::ot::igf Failed Tubulin Inhibitor Reformulated As Localized Adjuvant Therapy For Head And Neck Cancer$1.5M
Sep 2015Federal contractDefense · Igf::ot::igf SBIR Phase I 15.1 Army; Proposal A151-052-0822$100K

Show 4 earlier federal awards

Aug 2015Federal contractHealth and Human S · Igf::cl::igf Baa Contract Titled, "computational Drug Delivery: Leveraging Predictive Models To Develop Bioequivalent Generic Long-acting Injections."$695K
Sep 2014Federal contractHealth and Human S · Igf::ot::igf Failed Tubulin Inhibitor Reformulated As Localized Adjuvant Therapy For Head And Neck Cancer$223K
Sep 2014Federal contractDefense · Monthly Progress Report 1$999K
May 2013Federal contractDefense · SBIR Phase I Reasearch And Development For, "development Of A Long-acting, Injectable Controlled Release Butyrylcholinesterase Formulation Using Predictive Modeling."$149K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 502 peers

Line = median

Biotech · Molecule

Federal grants#5 · top 1%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 6

Sep 3, 2020PendingSustained Release Pharmaceutical Compositions and Methods of UseUSPTOApplication 16781797
Apr 25, 2019PendingSustained Release Pharmaceutical Compositions and Methods of UseUSPTOApplication 16162335
May 11, 2017PendingSustained Release Pharmaceutical Compositions And Methods Of UseUSPTOApplication 15349199

Show all 6 patent records

Sustained Release Pharmaceutical Compositions and Methods of UseSep 3, 2020 · Application 16781797Pending
Sustained Release Pharmaceutical Compositions and Methods of UseApr 25, 2019 · Application 16162335Pending
Sustained Release Pharmaceutical Compositions And Methods Of UseMay 11, 2017 · Application 15349199Pending
Sustained Release Pharmaceutical Compositions And Methods Of UseApplication PCTUS2016061625Pending
Sustained Release Pharmaceutical Compositions And Methods Of UseApplication 62341384Pending
Sustained Release Pharmaceutical Compositions And Methods Of UseApplication 62254015Pending

CELL MICROSYSTEMS INCSimilar federal contract value in Biotech · $5.1M in contracts
PLATELET BIOGENESIS, INCSimilar federal contract value in Biotech · $5M in contracts
AUTONOMOUS THERAPEUTICS INCSimilar federal contract value in Biotech · $4.9M in contracts
SIGMOVIR BIOSYSTEMS, INC.Similar federal contract value in Biotech · $4.9M in contracts
MIMEDX GROUP, INC.Similar federal contract value in Biotech · $4.8M in contracts
METACLIPSE THERAPEUTICS CORPSimilar federal contract value in Biotech · $4.7M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.